Ahammune Biosciences Funding

Pune-based biotech startup company, Ahammune Biosciences has raised an undisclosed amount in a Pre-Series A funding round led by Ideaspring Capital and Indian Angel Network, along with participation from Kotak Private Equity, Legacy Assets LLP (Baldota family fund), and Dr. Ajith Kamath (ex-Pfizer), and existing investors, including Dr. Anand Deshpande and Mr. Suman Kant Munjal. 

The Company also has Dr. Ganesh Natarajan as an existing investor and has received a funding grant from the Government of India’s body, BIRAC.

The recently raised funds will be utilized for “first-in-human” studies with Ahammune’s new drug candidate AB1001 for vitiligo. The study will include Phase-I safety studies in healthy human volunteers and Phase-II efficacy studies in vitiligo patients. The biotech company will also deploy the funds in building the patent portfolio to further the research and development efforts.

Vitiligo, a debilitating skin depigmentation disorder, has a global predominance of about 1-2 percent. The burden of the disease is enormous in India with certain regions having an occurrence rate of around 8 percent. Ahammune, established in May 2016, has filed its first Investigational New Drug (IND) Application with the Drug Controller General of India (DCGI) for approval to conduct human studies with its lead drug candidate for vitiligo.

Speaking about the latest investment, Dr. Parul Ganju, Co-founder and CEO of Ahammune Biosciences said, “Currently, there is no cure for vitiligo. Our drug aims to fulfill the unmet need in Vitiligo therapeutic. We have positioned it as a topical solution, a segment of the market that accounted for 54% of the total market share of available options. Our preclinical data suggest our drug candidate is very safe and can stop the spread of depigmentation and repigment white patches in animal models. Based on these studies, the first intended use of the drug will be in patients with non-segmental vitiligo, who have active vitiligo.”

Besides the treatment for vitiligo, the company is looking to target multiple dermatological indications with its deep pipeline of IP-based molecules that modulate cellular pathways underlying skin health and immunity.

“This disruptive scientific domain area of Ahammune thus has the potential and huge upside to provide a range of treatments for other immune-mediated diseases of the skin,” added Dr. Ganju.

“Effective Vitiligo treatment is presently an absolute unmet need and an unattended market. Millions of people are suffering because of this disease and the lack of available options. There is a tremendous need for a new drug with an upside of huge market potential. In addition to Vitiligo, Ahammune team can discover drugs for other autoimmune skin disorders like Atopic Dermatitis, Psoriasis, Scleroderma that have an even bigger market. We are very excited to be the first Institutional investor in Ahammune and back stellar founders Dr. Parul and Dr. K. Natarajan, Professor, School of Life Sciences, Jawaharlal Nehru University” said Naganand Doraswamy, MD Ideaspring Capital.

Padmaja Ruparel, Co-Founder at Indian Angel Network said, “Vitiligo is currently an unsolved problem and there is a real need for a new drug. This need represents a potential market size of $2.4 billion by the year 2024. Currently, first-line treatments are generic drugs like corticosteroids and immunosuppressants, manufactured by several companies throughout the world. There is no drug focused on curing vitiligo, which is approved by US-FDA and this presents a unique opportunity for the company. The team of Ahammune, led by Dr. Parul Ganju, has demonstrated a deep understanding of developing the drug and ensuring a high level of efficacy”

Don’t keep wondering about funding, you can also raise funds. Learn how to raise funds here: Yes I want to raise funds.

If you are an emerging startup and are looking for investors to raise funds, StartupLanes has its own angel network and investment banking services and is connected to angel investors and VCs in 15 countries that ensure that our member startups have easy access to external funds to scale up constantly.

You can subscribe to our news posts by entering your email in the box at the right side of this page.

The right investment is key to beating inflation and growing your wealth. Do you wish to become an angel investor? Yes, I want to be an angel investor.

Are you a startup and facing challenges in your business? Do you want to grow your business? It is not as difficult as it sounds. Learn how to grow your business here- Yes, I want to grow my business.

For publishing an advertorial article about your company on our website, drop an email at taniya@startuplanes.com